

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司 *
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

COSMETICS WITH KX-826 AS THE MAIN INGREDIENT

LAUNCH TO MARKET

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest development related to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that after receiving the designation for its in-house developed KX-826 from the International Nomenclature Cosmetic Ingredient (the “**INCI**”), the Company’s cosmetics with KX-826 as the main ingredient was officially launched into the international market recently. The first product is the topical anti-hair loss solution for androgenetic alopecia (the “**AGA**”) (the “**New Product**”). The Group will further explore the efficacy of KX-826 in the field of AGA and acne, actively enrich the product lines, increase market promotion to target users and meet customer requirements under different usage scenarios. The Company is of the view that the launch of the New Product will provide a solid stream of revenue and cash flow to the Group, benefiting the Group as a whole in the long term.

KX-826 is one of the core innovative products of the Group. During the course of its development, it has been used to complete multiple clinical trials for the treatment of male and female AGA in China and the United States. It has demonstrated excellent safety profile and remarkable therapeutic effects in anti-hair loss and new hair growth. The launch of the New Product is the first commercialization attempt of KX-826 in the field of dermatology, representing the Group’s transition from R&D stage to commercialization stage. Going forward, the Company will further commercialize its cosmetics products worldwide, providing more convenient and effective products to consumers with the demand

of anti-hair loss and new hair growth. In the future, the Group plans to allocate more resources to enhance the Group's commercialization capabilities to boost brand awareness, capture market dynamics and increase the penetration rate of the products.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: Apart from the New Product, there is no assurance that other products of KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 10 July 2024

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

** For identification purpose only*